Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

24 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Molecular and cellular mechanisms of receptor-mediated endocytosis.
Brown VI, Greene MI. Brown VI, et al. DNA Cell Biol. 1991 Jul-Aug;10(6):399-409. doi: 10.1089/dna.1991.10.399. DNA Cell Biol. 1991. PMID: 1648927 Review.
Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease.
Brown VI, Seif AE, Reid GS, Teachey DT, Grupp SA. Brown VI, et al. Immunol Res. 2008;42(1-3):84-105. doi: 10.1007/s12026-008-8038-9. Immunol Res. 2008. PMID: 18716718 Free PMC article. Review.
Demonstration by two-color flow cytometry that tyrosine kinase activity is required for down-modulation of the oncogenic neu receptor.
Brown VI, Shah N, Smith R, Hellman M, Jarett L, Mikami Y, Cohen E, Qian X, Greene MI. Brown VI, et al. DNA Cell Biol. 1994 Feb;13(2):193-209. doi: 10.1089/dna.1994.13.193. DNA Cell Biol. 1994. PMID: 7910024
The role of the neu oncogene product in cell transformation and normal development.
Kokai Y, Wada T, Myers JN, Brown VI, Dobashi K, Cohen J, Hamuro J, Weiner DB, Greene MI. Kokai Y, et al. Among authors: brown vi. Princess Takamatsu Symp. 1988;19:45-57. Princess Takamatsu Symp. 1988. PMID: 2908355 Review.
Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts.
Kokai Y, Myers JN, Wada T, Brown VI, LeVea CM, Davis JG, Dobashi K, Greene MI. Kokai Y, et al. Among authors: brown vi. Cell. 1989 Jul 28;58(2):287-92. doi: 10.1016/0092-8674(89)90843-x. Cell. 1989. PMID: 2568888
Anti-receptor antibodies reverse the phenotype of cells transformed by two interacting proto-oncogene encoded receptor proteins.
Wada T, Myers JN, Kokai Y, Brown VI, Hamuro J, LeVea CM, Greene MI. Wada T, et al. Among authors: brown vi. Oncogene. 1990 Apr;5(4):489-95. Oncogene. 1990. PMID: 1970151
Carboxyl-terminal deletion and point mutations decrease the transforming potential of the activated rat neu oncogene product.
Mikami Y, Davis JG, Dobashi K, Dougall WC, Myers JN, Brown VI, Greene MI. Mikami Y, et al. Among authors: brown vi. Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7335-9. doi: 10.1073/pnas.89.16.7335. Proc Natl Acad Sci U S A. 1992. PMID: 1354355 Free PMC article.
A single-center study of hematopoietic stem cell transplantation for primary immune deficiencies (PIDD).
Dinardo L, Brown V, Perez E, Bunin N, Sullivan KE. Dinardo L, et al. Among authors: brown v. Pediatr Transplant. 2012 Feb;16(1):63-72. doi: 10.1111/j.1399-3046.2011.01606.x. Epub 2011 Nov 17. Pediatr Transplant. 2012. PMID: 22093026
Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies.
Barrett D, Brown VI, Grupp SA, Teachey DT. Barrett D, et al. Among authors: brown vi. Paediatr Drugs. 2012 Oct 1;14(5):299-316. doi: 10.2165/11594740-000000000-00000. Paediatr Drugs. 2012. PMID: 22845486 Free PMC article. Review.
mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia.
Teachey DT, Sheen C, Hall J, Ryan T, Brown VI, Fish J, Reid GS, Seif AE, Norris R, Chang YJ, Carroll M, Grupp SA. Teachey DT, et al. Among authors: brown vi. Blood. 2008 Sep 1;112(5):2020-3. doi: 10.1182/blood-2008-02-137141. Epub 2008 Jun 10. Blood. 2008. PMID: 18544682 Free PMC article.
24 results
Jump to page